Earnings Feed
Start Free
Lyell Immunopharma, Inc.·4

Feb 11, 9:04 PM ET

Lee Gary K. 4

Research Summary

AI-generated summary

Updated

Lyell (LYEL) CSO Gary K. Lee Receives 54,000-Share Awards

What Happened Gary K. Lee, Chief Scientific Officer of Lyell Immunopharma (LYEL), received awards totaling 54,000 shares (4,000 shares issued and a separate 50,000-share award recorded) and sold 147 shares in an open-market-type transaction. The 4,000 shares were issued on Feb 9, 2026 upon certification of performance-based RSUs; the 50,000-share award (recorded Feb 10, 2026) is listed as a derivative/award subject to vesting. The 147 shares were disposed of on Feb 10, 2026 at $23.12 each for proceeds of $3,399 — the filing notes the sale was to cover tax withholding on vested RSUs.

Key Details

  • Transaction dates and prices:
    • Feb 9, 2026: 4,000 shares issued (award) at $0.00 (performance-based RSUs certified and settled).
    • Feb 10, 2026: 147 shares sold at $23.12 each, proceeds $3,399 (automatic sale to cover taxes).
    • Feb 10, 2026: 50,000-share award recorded at $0.00 (derivative/subject to vesting).
  • Shares owned after transaction: Not specified in the provided filing excerpt.
  • Relevant footnotes:
    • F1: 4,000 shares were performance-based RSUs granted Feb 9, 2024 and issued upon achievement of performance criteria certified on Feb 9, 2026.
    • F2: Ownership totals include 390 shares from the 2021 Employee Stock Purchase Plan (acquired Nov 18, 2025).
    • F3: The 147-share sale was an automatic sale to satisfy tax withholding from RSU settlement.
    • F4: The derivative award is subject to vesting: 12.5% vests six months after Feb 9, 2026, then 1/48th vests monthly thereafter, subject to continued service.
  • Filing: Report filed Feb 11, 2026 (appears timely relative to the Feb 9–10 transactions).

Context

  • The 147-share sale was a tax-withholding/cashless-type disposition tied to RSU settlement — a routine administrative sale rather than a directional bet on the stock.
  • The larger items are awards/derivatives (54,000 shares total recorded), not open-market purchases. The 50,000-share award will vest over time per the schedule in F4 and requires continued service.
  • These filings are factual disclosures of insider transactions and do not, by themselves, indicate insider sentiment or a trading strategy.